Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy
Journal of Viral Hepatitis · 2023
DOI: 10.1111/jvh.13844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Arka De und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Coinfection, Hepatitis C, Chronic, Hepatitis C, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is more prevalent in people living with HIV‐AIDS (PLHA) and portends a poorer prognosis. Pharmacokinetic studies suggest the absence of significant interaction between velpatasvir and dolutegravir which has been recently recommended as part of preferred first‐line antiretroviral therapy (ART) regimens by WHO. However, clinical data on the use of velpatasvir‐based regimen in PLHA taking dolutegavir is lacking. Hence, we aimed to assess the efficacy and safety of sofosbuvir and velpatasvir (SOF + VEL) in HCV and HIV coinfected patients on dolutegravir‐based ART. Forty‐five consecutive PLHA with HCV coinfection on dolutegravir‐based ART were prospectively enrolled. All patients were treated SOF + VEL for 12 weeks. Complete haemogram, liver and renal function tests were assessed at baseline, 4 weeks and at end of treatment. Sustained virological response (SVR) was assessed at 12 weeks after end of treatment. The majority were males (95.5%) with a mean age of 32.8 ± 12.3 years. Cirrhosis was present in 6 (13.3%) patients. All patients completed 12 weeks of therapy with SOF + VEL, but SVR could not be assessed in two patients. Forty‐two (97.7%) of the remaining 43 patients attained SVR‐12. SVR‐12 rate was 97.7% and 93.3% by per protocol and intention to treat analysis, respectively. No grade III/IV adverse events were reported, and there was no worsening of blood counts, liver or renal function test parameters. The pan‐genotypic regimen of SOF + VEL is safe and effective in PLHA with HCV coinfection who are on dolutegravir‐based ART.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Madhumita Premkumar, Virendra Singh, Ajay Duseja
Zitieren
APA
De, A., Charak, S., Bhagat, N., Rathi, S., Verma, N., Premkumar, M., Taneja, S., Sharma, A., Goel, K., Singh, V., & Duseja, A. (2023). Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13844
Vancouver
De A, Charak S, Bhagat N, Rathi S, Verma N, Premkumar M, et al. Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13844
BibTeX
@article{De2023,
author = {De, Arka and Charak, Swati and Bhagat, Naveen and Rathi, Sahaj and Verma, Nipun and Premkumar, Madhumita and Taneja, Sunil and Sharma, Aman and Goel, Kapil and Singh, Virendra and Duseja, Ajay},
title = {Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy},
journal = {Journal of Viral Hepatitis},
year = {2023},
doi = {10.1111/jvh.13844}
}
EUVIMED